Leah M. Marcotte, MD, Jeffrey Krimmel-Morrison, MD, and Joshua M. Liao, MD, MSc
Individuals can underperform in circumstances of shared accountability. In clinical settings, this is an unintended consequence of the health care sector’s complexity fragmentation.
AMA J Ethics. 2020;22(9):E802-807. doi:
10.1001/amajethics.2020.802.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
A look at current literature and work by a statewide initiative can motivate development of policies that help respond to unrepresented patients’ needs.
AMA J Ethics. 2019;21(7):E611-616. doi:
10.1001/amajethics.2019.611.
When patients are unable to express their wishes and do not have surrogates or advance directives, which and whose values should inform decision making for them? We discuss ethical complexities of caring for unrepresented patients.
Dr Jing Li joins Ethics Talk to discuss her article, coauthored with Dr Robert Tyler Braun, Sophia Kakarala, and Dr Holly G. Prigerson: “How Should Cost-Informed Goals of Care Decisions Be Facilitated at Life’s End?”